Special Issues

Pharmacological Treatment of Cardiomyopathy: Progress and Challenges
Editor: Ivan Srejovic

Submission Deadline: 15 February 2024 (Status: Open)

Special Issue Editor

Dr. Ivan Srejovic      Email   |   Website
1. Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2. Center of Excellence for Redox Balance Research in Cardiovascular and Metabolic Disorders, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Interests: cardiovascular system; oxidative stress; nitric oxide; glutamate receptors; galectin-3; conditioning phenomenon; ischemia/reperfusion injury; metabolic disorders; diabetes mellitus

Special Issue Information

Dear Colleagues,

Homeostatic regulation of cardiomyocytes plays a crucial role in maintaining normal physiological activity of cardiac tissue. Heart disease is a significant burden on global health care systems, it is the leading cause of death worldwide. Clinical symptoms can range from asymptomatic to systolic and diastolic ventricular dysfunction, arrhythmias, and sudden cardiac death. There are many types of cardiomyopathy. The most common pathological findings described in the literature are hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, restrictive cardiomyopathy, left ventricular noncompaction, and Takotsubo cardiomyopathy (broken heart syndrome). Although a great effort is being made to understand the pathogenesis of various types of cardiomyopathy, there are a large number of limitations that challenge the research and development of an adequate therapeutic approach. Numerous factors mutually contribute to the emergence of heart disturbances at multiple levels, which ultimately results in cardiomyopathy. The goal of the constant search for either new and more effective pharmacological or non pharmacological solutions is to alleviate the symptoms and to prevent sudden cardiac death.

Ivan Srejovic
Guest Editor


cardiac redox regulation; heart signaling; toxic cardiomyopathy; chemo/radiation cardiac injury; diabetes and heart dysfunction; hypertensive cardiomyopathy; arrhythmogenic cardiomyopathy; restrictive cardiomyopathy; dilated cardiomyopathy

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Publication year
Article type
Sort by Default Latest Most read